Shots:
- PRISM has partnered with Receptor.AI to develop an AI-navigated, physics-guided platform for discovering orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins & complex receptor systems
- Collaboration will combine PRISM’s PepMetics Tech, 3D small molecules designed to mimic α-helix & β-turn motifs, with Receptor.AI’s AI-driven molecular design engine to identify hit, lead, & clinical candidate compounds
- The partners will initially focus on a receptor target for metabolic diseases incl. obesity, with Receptor.AI leading molecular design & both companies will engage pharma partners interested in leveraging the combined capabilities of both technologies
Ref: Businesswire | Image: PRISM & Receptor.AI | Press Release
Related News: George Medicines Partners with Ahngook Pharmaceutical to Commercialize GMRx2 in Korea
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
